The focus of Project 2 will be to better understand the role of microglial cells in the generation and progression of neurodegenerative change in the human brain. These cells are a vital driving component of the cytokine cycle that forms the core of this research program. We hypothesize that microglial activation plays a central role on the development and progression of pathology in common neurodegenerative disorders such as Alzheimer's and Parkinson's disease (AD and PD) and that the extent of the microglial reaction is modulated by a number of different factors including the genotype of the individual and the local tissue environment. To achieve this objective we will study the microglial reaction in a number of unique human tissue cohorts at the transcriptomic, protein, and tissue morphology level.
In Aim 1 we will compare and contrast microglial and inflammatory gene expression levels in cases of AD, PD, Parkinsonian dementia and dementia with Lewy bodies (DLB) using microarray techniques. Included in the analysis of AD cases will be post-mortem tissue from 9 patients treated with Ap as part of the Elan 102 trial. Genes with significantly altered expression will then be further investigated in the tissue using immunocytochemistry.
In Aim 2 we will continue our investigations of the effect of ApoE gene polymorphisms on the extent of microglial pathology by studying the CFAS cohort, a large UK cohort of 450 unselected elderly individuals who have been followed in the community and for whom detailed prospective clinical and pathological data are available. By using a panel of microglial antibodies we will generate phenotypic profiles of microglia in the different degenerative disorders. In addition we will continue our investigations of the apparent differential response of grey and white matter microglial populations after severe head injury. Successful completion of these aims in conjunction with Core B and Project 3, will provide valuable information about the role of microglia in these neurodegenerative conditions, the effect of ApoE genotype on the pathology seen and the effects of the local tissue environment on the activation of microglia.
|Wang, Wei; Bodles-Brakhop, Angela M; Barger, Steven W (2016) A Role for P-Glycoprotein in Clearance of Alzheimer Amyloid Î² -Peptide from the Brain. Curr Alzheimer Res 13:615-20|
|Mao, Xianrong; Phanavanh, Bounleut; Hamdan, Hamdan et al. (2016) NFÎºB-inducing kinase inhibits NFÎºB activity specifically in neurons of the CNS. J Neurochem 137:154-63|
|Zawada, W Michael; Mrak, Robert E; Biedermann, JoAnn et al. (2015) Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation. Acta Neuropathol Commun 3:9|
|Aboud, Orwa; Aboud, Talal; Janjua, M Burhan et al. (2015) Image-Guided Spinal Navigation for C1-C2 Instrumentation: Part I. Contemp Neurosurg 37:1-6|
|Deng, Juan; Habib, Ahsan; Obregon, Demian F et al. (2015) Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3Î² signaling pathway. J Neurochem 135:630-7|
|Pey, Peixuan; Pearce, Ronald K B; Kalaitzakis, Michail E et al. (2014) Phenotypic profile of alternative activation marker CD163 is different in Alzheimer's and Parkinson's disease. Acta Neuropathol Commun 2:21|
|Aboud, Orwa; Griffin W, Sue T (2014) Silver Staining of Alzheimer's Disease. J Neurol Disord 2:|
|Kuang, Xiu-Li; Liu, Fang; Chen, Huifang et al. (2014) Reductions of the components of the calreticulin/calnexin quality-control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease. J Neurosci Res 92:1319-29|
|Zhang, Hanying; Okamoto, Miyako; Panzhinskiy, Evgeniy et al. (2014) PKCÎ´/midkine pathway drives hypoxia-induced proliferation and differentiation of human lung epithelial cells. Am J Physiol Cell Physiol 306:C648-58|
|Barger, Steven W (2013) Apolipoprotein E acts at pre-synaptic sites...among others. J Neurochem 124:1-3|
Showing the most recent 10 out of 131 publications